Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
Authors:
Top Cited Papers
- 1 March 2017
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 18 (3) , 404-412
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell CarcinomaThe Oncologist, 2016
- Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic InnovationsCurrent Dermatology Reports, 2014
- Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus SyndromeNew England Journal of Medicine, 2012
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Clinical Experience With Hedgehog Pathway InhibitorsJournal of Clinical Oncology, 2010
- Nevoid basal cell carcinoma syndrome (Gorlin syndrome)Orphanet Journal of Rare Diseases, 2008
- Basal cell carcinomas: attack of the hedgehogNature Reviews Cancer, 2008
- Basal-Cell CarcinomaNew England Journal of Medicine, 2005